2022 ICD-10-CM Diagnosis Code C22.0: Liver Cell Carcinoma
Toggle navigation
Search All ICD-10 Toggle Dropdown
- Search All ICD-10
- ICD-10-CM Diagnosis Codes
- ICD-10-PCS Procedure Codes
- ICD-10-CM Diagnosis Index
- ICD-10-CM External Causes Index
- ICD-10-CM Table of Drugs
- ICD-10-CM Table of Neoplasms
- HCPCS Codes
- ICD-9-CM Diagnosis Codes
- ICD-9-Vol-3 Procedure Code
- Search All Data
2026
- ICD-10-CM Codes ›
- C00-D49 ›
- C15-C26 ›
- C22- ›
- 2026 ICD-10-CM Diagnosis Code C22.0
Liver cell carcinoma
- 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Billable/Specific Code
- C22.0 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
- The 2026 edition of ICD-10-CM C22.0 became effective on October 1, 2025.
- This is the American ICD-10-CM version of C22.0 - other international versions of ICD-10 C22.0 may differ.
- Hepatocellular carcinoma
- Hepatoma
- Applicable To annotations, or
- Code Also annotations, or
- Code First annotations, or
- Excludes1 annotations, or
- Excludes2 annotations, or
- Includes annotations, or
- Note annotations, or
- Use Additional annotations
- C00-D49 2026 ICD-10-CM Range C00-D49
NeoplasmsNote
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
- C15-C26 2026 ICD-10-CM Range C15-C26
Malignant neoplasms of digestive organsType 1 Excludes
- Kaposi's sarcoma of gastrointestinal sites (C46.4)
- gastrointestinal stromal tumors (C49.A-)
- C22 ICD-10-CM Diagnosis Code C22
Malignant neoplasm of liver and intrahepatic bile ducts
- 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Non-Billable/Non-Specific Code
- malignant neoplasm of biliary tract NOS (C24.9)
- secondary malignant neoplasm of liver and intrahepatic bile duct (C78.7)
- code to identify:
- alcohol abuse and dependence (F10.-)
- hepatitis B (B16.-, B18.0-B18.1)
- hepatitis C (B17.1-, B18.2)
- Cancer of the liver, hepatocellular
- Liver cell carcinoma (clinical)
- (hep-a-toe-ma) a liver tumor.
- (hep-a-toe-sel-yoo-ler kar-sin-o-ma) a type of adenocarcinoma, the most common type of liver tumor.
- A malignant neoplasm arising from hepatocytes.
- A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all african countries south of the sahara and in southeast asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis b, hepatitis c, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.
- A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with epithelial cells indistinguishable from normal hepatocytes to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form giant cells. Several classification schemes have been suggested.
- A type of adenocarcinoma and the most common type of liver tumor.
- New abnormal liver tissue that grows by excessive cellular division and proliferation more rapidly than normal and continues to grow after the stimuli that initiated the new growth cease; do not confuse with intrahepatic neoplasm as that may refer to bile duct neoplasm (biliary tract neoplasm).
- Primary malignant neoplasm of epithelial liver cells; it ranges from a well-differentiated tumor with epithelial cells indistinguishable from normal hepatocytes to a poorly differentiated neoplasm; the cells may be uniform or markedly pleomorphic, or form giant cells; associations exist with chronic hepatitis b virus infection, some types of cirrhosis, and hepatitis c virus infection.
- Tumors or cancer of the liver.
- 435 Malignancy of hepatobiliary system or pancreas with mcc
- 436 Malignancy of hepatobiliary system or pancreas with cc
- 437 Malignancy of hepatobiliary system or pancreas without cc/mcc
Convert C22.0 to ICD-9-CM
Code History- 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
- 2017 (effective 10/1/2016): No change
- 2018 (effective 10/1/2017): No change
- 2019 (effective 10/1/2018): No change
- 2020 (effective 10/1/2019): No change
- 2021 (effective 10/1/2020): No change
- 2022 (effective 10/1/2021): No change
- 2023 (effective 10/1/2022): No change
- 2024 (effective 10/1/2023): No change
- 2025 (effective 10/1/2024): No change
- 2026 (effective 10/1/2025): No change
Diagnosis Index entries containing back-references to C22.0:
- Cancer - see also Neoplasm, by site, malignant
- hepatocellular C22.0
- Carcinoma (malignant) - see also Neoplasm, by site, malignant
- bile duct
- with hepatocellular, mixed C22.0
- hepatocellular C22.0
- with bile duct, mixed C22.0
- fibrolamellar C22.0
- hepatic cell C22.0
- hepatocholangiolitic C22.0
- liver cell C22.0
- bile duct
- Cholangiocarcinoma
- with hepatocellular carcinoma, combined C22.0
- Cholangiohepatoma C22.0
- Embryoma - see also Neoplasm, uncertain behavior, by site
- malignant - see also Neoplasm, malignant, by site
- liver C22.0
- liver C22.0
- malignant - see also Neoplasm, malignant, by site
- Hepatocarcinoma C22.0
- Hepatocholangiocarcinoma C22.0
- Hepatoma (malignant) C22.0
- embryonal C22.0
Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.
Advertise with Us | License ICD10 Data | Medical billing and coding classes
Copyright © | ICD10data.com
Từ khóa » C22 0
-
C22.0 - Liver Cell Carcinoma | ICD-10-CM - Unbound Medicine
-
C22.1 Intrahepatic Bile Duct Carcinoma - ICD-10 Version:2019
-
ICD-10 Code For Liver Cell Carcinoma- C22.0- Codify By AAPC
-
ICD-10-Code: C22.0 Leberzellkarzinom
-
ICD-10 | Liver Cell Carcinoma (C22.0)
-
[PDF] SC220_E-ICD-10-C22.0-Liver-cell-carcinoma-survival.pdf
-
And C24:0-dihydroceramides Confer Mixed Cytotoxicity In T-cell ...
-
C22.0 - Liver Cell Carcinoma - Turquoise Health MS-DRG Manual
-
Clinical Modification - Liver Cell Carcinoma - Classes | NCBO BioPortal
-
Docosanoic Acid, C22:0 Fatty Acid | Lipids And Biochemicals
-
Defining Diagnostic Cutoffs In Neurological Patients For Serum Very ...
-
POX Fatty Acid Profile, Peroxisomal (C22-C26), Serum
-
ICD-O-3 Site Codes - SEER Training
-
Docosanoic Acid - Cayman Chemical